These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

162 related items for PubMed ID: 6339985

  • 1. Controlled trial of pergolide mesylate in Parkinson's disease and progressive supranuclear palsy.
    Jankovic J.
    Neurology; 1983 Apr; 33(4):505-7. PubMed ID: 6339985
    [Abstract] [Full Text] [Related]

  • 2. A multicenter double-blind placebo-controlled trial of pergolide as an adjunct to Sinemet in Parkinson's disease.
    Olanow CW, Fahn S, Muenter M, Klawans H, Hurtig H, Stern M, Shoulson I, Kurlan R, Grimes JD, Jankovic J.
    Mov Disord; 1994 Jan; 9(1):40-7. PubMed ID: 8139604
    [Abstract] [Full Text] [Related]

  • 3. Double-blind trial of pergolide for Parkinson's disease.
    Diamond SG, Markham CH, Treciokas LJ.
    Neurology; 1985 Mar; 35(3):291-5. PubMed ID: 3883232
    [Abstract] [Full Text] [Related]

  • 4. Double-blind controlled study of pergolide mesylate as an adjunct to Sinemet in the treatment of Parkinson's disease.
    Olanow CW, Alberts MJ.
    Adv Neurol; 1987 Mar; 45():555-60. PubMed ID: 3548266
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Progressive supranuclear palsy: clinical features and response to treatment in 16 patients.
    Jackson JA, Jankovic J, Ford J.
    Ann Neurol; 1983 Mar; 13(3):273-8. PubMed ID: 6847139
    [Abstract] [Full Text] [Related]

  • 9. Efficacy of pergolide and mesulergine.
    Lieberman AN, Gopinathan G, Neophytides A.
    Eur Neurol; 1986 Mar; 25(2):86-90. PubMed ID: 3948891
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Pergolide in the treatment of Parkinson's disease.
    Quinn NP, Lang AE, Thompson C, Brincat S, Marsden CD, Parkes JD.
    Adv Neurol; 1984 Mar; 40():509-13. PubMed ID: 6695628
    [No Abstract] [Full Text] [Related]

  • 12. Treatment of advanced Parkinson disease with pergolide.
    Lieberman A, Goldstein M, Leibowitz M, Neophytides A, Kupersmith M, Pact V, Kleinberg D.
    Neurology; 1981 Jun; 31(6):675-82. PubMed ID: 7195484
    [Abstract] [Full Text] [Related]

  • 13. Long-term efficacy of pergolide in patients with Parkinson's disease.
    Sage JI, Duvoisin RC.
    Clin Neuropharmacol; 1986 Jun; 9(2):160-4. PubMed ID: 3708601
    [Abstract] [Full Text] [Related]

  • 14. Placebo-controlled study of mesulergine in Parkinson's disease.
    Jankovic J, Orman J, Jansson B.
    Neurology; 1985 Feb; 35(2):161-5. PubMed ID: 3881692
    [Abstract] [Full Text] [Related]

  • 15. Pergolide mesylate: new therapy for Parkinson disease.
    Tanner CM, Klawans HL.
    Ann Intern Med; 1982 Apr; 96(4):522-3. PubMed ID: 7065569
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Pergolide for levodopa-induced complications in Parkinson's disease.
    Clarke C E, Speller J M.
    Cochrane Database Syst Rev; 2000 Apr; (2):CD000235. PubMed ID: 10796704
    [Abstract] [Full Text] [Related]

  • 19. Pergolide mesylate and idiopathic Parkinson disease.
    Tanner CM, Goetz CG, Glantz RH, Glatt SL, Klawans HL.
    Neurology; 1982 Oct; 32(10):1175-9. PubMed ID: 6889702
    [Abstract] [Full Text] [Related]

  • 20. Analysis of mortality in pergolide-treated patients with Parkinson's disease.
    Sayler ME, Street JS, Bosomworth JC, Potvin JH, Kotsanos JG.
    Neuroepidemiology; 1996 Oct; 15(1):26-32. PubMed ID: 8719046
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 9.